title: How Do Decision Makers in Europe Value Other Economic Evaluation Tools Than Cost-Effectiveness Analysis for Vaccines?
authors.affiliation: Deloitte, Diegem, Belgium.
authors.forename: J M
authors.initials: JM
authors.lastname: Höhne
authors.affiliation: GlaxoSmithKline Vaccines, Wavre, Belgium.
authors.forename: N
authors.initials: N
authors.lastname: Demarteau
authors.affiliation: Deloitte, Diegem, Belgium.
authors.forename: Ö
authors.initials: Ö
authors.lastname: Saka
authors.affiliation: GlaxoSmithKline Vaccines, Wavre, Belgium.
authors.forename: B
authors.initials: B
authors.lastname: Standaert
authors.affiliation: London School of Economics and Political Science, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Kleintjens